Lexeo Therapeutics (LXEO) Non-Current Assets (2022 - 2026)

Lexeo Therapeutics has reported Non-Current Assets for 5 years, with the latest figure at $49.5 million in Q1 2026.

• Quarterly Non-Current Assets rose 142.43% year-over-year to $49.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $181.8 million (up 157.93% YoY) and the FY2025 annual result came in at $80.3 million, up 285.65% from the prior year.
• Non-Current Assets retreated to $49.5 million in Q1 2026 per LXEO's latest filing, from $80.3 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $80.3 million in Q4 2025 and troughed at $14.4 million in Q3 2024.
• A 5-year average of $26.3 million and a median of $16.5 million in 2022 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets dropped 9.1% in 2024, then jumped 285.65% in 2025.
• Over 5 years, Non-Current Assets stood at $17.0 million in 2022, then decreased by 8.9% to $15.5 million in 2023, then surged by 34.22% to $20.8 million in 2024, then surged by 285.65% to $80.3 million in 2025, then plunged by 38.36% to $49.5 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $49.5 million, $80.3 million, and $16.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.